Excellos, Lonza, and Akadeum Life Sciences have announced a new project aimed at redefining standards for cell therapy manufacturing by elevating the role of starting material quality.
This project brings together leaders in donor cell characterisation, automated manufacturing, and cell separation technology to explore how aligned, modular innovation can streamline workflows and improve outcomes across the cell and gene therapy (CGT) landscape.
Together, the companies are working to spotlight the value of flexible, integrated platforms—from donor sourcing through manufacturing. The project is intended to emphasise how upstream quality impacts downstream performance, and clinical consistency.
Excellos brings its donor-to-dose capabilities—including donor management, apheresis, cell characterization, and GMP manufacturing—while Akadeum contributes its gentle, flotation-based cell separation technology and Lonza offers the Cocoon® Platform, a functionally closed, automated manufacturing system enabling decentralized scale-up.
While early conversations are exploring the technical feasibility of combining these approaches into a single modular workflow, the immediate focus is on sharing best practices and aligned innovation strategies across upcoming industry events.
